Belfast Health and Social Caree Trust licensee HiberGene Diagnostics Ltd has raised €2m. The company will use this round of funding to support the commercialisation of its first two rapid molecular tests for Meningococcal Meningitis and Group B Streptococcus, which were developed at the Royal Victoria Hospital in Belfast and which it has licenced from Belfast HSC Trust.